External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Aurobindo Pharma (ARBP) reported a 9.4% YoY increase in consolidated revenue (Ex-Natrol) in Q1FY23, primarily due to a 10.8% YoY increase in the US business and 3% YoY increase in Growth markets.</li><li>ARV increased by 28.1% YoY and API, up 12% YoY, increased the topline.</li><li>However, the US sales of $386 Mn (vs. exp. $375 Mn) have incresaed by 6.0% YoY due to additional volume for certain products and incremental volume in existing segments like antibiotics.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Aurobindo Pharma (ARBP) reported a 9.4% YoY increase in consolidated revenue (Ex-Natrol) in Q1FY23, primarily due to a 10.8% YoY increase in the US business and 3% YoY increase in Growth markets.ARV increased by 28.1% YoY and API, up 12% YoY, increased the topline.However, the US sales of $386 Mn (vs. exp. $375 Mn) have incresaed by 6.0% YoY due to additional volume for certain products and incremental volume in existing segments like antibiotics.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma Ltd - Profitability Hits Due To High Input Costs